HDL cholesterol: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett (HDL cholesterol efflux capacity) |
||
| Line 4: | Line 4: | ||
Low HDL is part of [[hypoalphalipoproteinemia]]. | Low HDL is part of [[hypoalphalipoproteinemia]]. | ||
The HDL cholesterol efflux capacity, "the ability of HDL to accept cholesterol from macrophages, which is a key step in reverse cholesterol transport" may be a more important biomarker than the HDL level at predicting cardiovascular events.<ref name="pmid25404125">{{cite journal| author=Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE et al.| title=HDL cholesterol efflux capacity and incident cardiovascular events. | journal=N Engl J Med | year= 2014 | volume= 371 | issue= 25 | pages= 2383-93 | pmid=25404125 | doi=10.1056/NEJMoa1409065 | pmc=PMC4308988 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25404125 }} </ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 05:36, 15 February 2015
In physiology, HDL cholesterol (HDL) is "cholesterol which is contained in or bound to high-density lipoproteins (HDL), including cholesterol esters and free cholesterol."[1]
It is not clear whether insufficient HDL causes coronary artery disease[2] and raising the HDL does not seem to reduce coronary artery disease.[3]
Low HDL is part of hypoalphalipoproteinemia.
The HDL cholesterol efflux capacity, "the ability of HDL to accept cholesterol from macrophages, which is a key step in reverse cholesterol transport" may be a more important biomarker than the HDL level at predicting cardiovascular events.[4]
References
- ↑ Anonymous (2024), HDL cholesterol (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK et al. (2012). "Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.". Lancet. DOI:10.1016/S0140-6736(12)60312-2. PMID 22607825. Research Blogging.
- ↑ AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P et al. (2011). "Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.". N Engl J Med 365 (24): 2255-67. DOI:10.1056/NEJMoa1107579. PMID 22085343. Research Blogging.
- ↑ Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE et al. (2014). "HDL cholesterol efflux capacity and incident cardiovascular events.". N Engl J Med 371 (25): 2383-93. DOI:10.1056/NEJMoa1409065. PMID 25404125. PMC PMC4308988. Research Blogging.